The groundbreaking success of the copyright undeniably transformed the pharmaceutical landscape, but placing funds in companies heavily reliant on off-patent versions presents a challenging picture. Despite early profits were impressive, the cessation of patents and the rise of cheaper alternatives have eroded the customer base. Therefore, a thorou